Dawn of antioxidants and immune modulators to stop HIV-progression and boost the immune system in HIV/AIDS patients: An updated comprehensive and critical review

Pharmacological Reports

Volumn 67, Issue 3, 2015, Pages 600-605

  Singh, Gurinder ^a   Pai, Roopa S ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

AVR118; Cytolin; Immunitin (HE2000); Interleukin 7; Murabutide; Resveratrol; Reticulose; Setarud; Tucaresol

Indexed keywords

ANTIOXIDANT; AVR 118; CYTOLIN; IMMUNITIN; IMMUNOMODULATING AGENT; INTERLEUKIN 7; MONOCLONAL ANTIBODY; MURABUTIDE; NUCLEIC ACID; RESVERATROL; RETICULASE; SETARUD; TUCARESOL; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOMODULATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMAL; DRUG EFFECTS; HIV INFECTIONS; IMMUNOLOGY; OXIDATIVE STRESS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIOXIDANTS; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; OXIDATIVE STRESS;

EID: 84924965932     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.12.007     Document Type: Review

References (73)

1. L.N. Ramana, A.R. Anand, S. Sethuraman, and U. Krishnan Targeting strategies for delivery of anti-HIV drugs J Control Release 192 2014 271 283
2. A.A. Date, and C.J. Destache A review of nanotechnological approaches for the prophylaxis of HIV/AIDS Biomaterials 34 26 2013 6202 6228
3. R.W. Buckheit Jr., K.M. Watson, K.M. Morrow, and A.S. Ham Development of topical microbicides to prevent the sexual transmission of HIV Antiviral Res 85 1 2010 142 158
4. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf [accessed 17.05.14]
5. C.A. Hankins, and M.R. Dybul The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review Curr Opin HIV AIDS 8 1 2013 50 58
6. V.K. Jain, and R.K. Chandra Does nutritional deficiency predispose to acquired immune deficiency syndrome? Nutr Res 4 1984 537 543
7. Task Force on Nutrition Support in AIDS Guidelines for nutrition support in AIDS Nutrition 5 1 1989 39 46
8. A.M. Tang, and E. Smit Selected vitamins in HIV infection: a review AIDS Patient Care STDS 12 4 1998 263 273
9. R.T. Sepulveda, and R.R. Watson Treatment of antioxidant deficiencies in AIDS patients Nutr Res 22 1-2 2002 27 37
10. M. Garland, and W.W. Fawzi Antioxidants and progression of human immunodeficiency virus (HIV) disease Nutr Res 19 8 1999 1259 1276
11. G.W. Pace, and C.D. Leaf The role of oxidative stress in HIV disease Free Radic Biol Med 19 4 1995 523 528
12. A. Bendich Antioxidant nutrients and immune functions - introduction Adv Exp Med Biol 262 1990 1 12
13. A. Bendich Role of antioxidants in the maintenance of immune functions B. Frei, Natural antioxidants in human health and disease 1994 Academic Press San Diego, CA 447 467
14. G. Singh, and R.S. Pai Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS J Control Release 194 2014 178 188
15. http://aidsinfo.nih.gov/drugs/531/tucaresol/0/patient [accessed 07.10.14]
16. S.A. SeyedAlinaghi, K. Paydary, S. Emamzadeh-Fard, and M. Mohraz Treatment with IMODTM as a novel immune modulator in HIV positive patients J AIDS Clinic Res 3 2012 180 10.4172/2155-6113.1000180
17. P. Kheirandish, M. Mohraz, B. Farzamnfar, M. Abdollahi, M.H. Shahhosseiny, and H. Madani et al. Preclinical and phase 1 clinical safety of Setarud (IMOD), a novel immunomodulator DARU J Pharm Sci 17 3 2009 148 156
18. M. Mohraz, P. Kheirandish, P.A. Kazerooni, M.A. Davarpanah, M.H. Shahhosseiny, and B. Mahdavian et al. A clinical trial on the efficacy of IMOD in AIDS patients DARU J Pharm Sci 17 4 2009 277 284
19. Z. Jakopin Murabutide revisited: a review of its pleiotropic biological effects Curr Med Chem 20 16 2013 2068 2079
20. E.M. Jackson, and M.M. Herbst-Kralovetz Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine PLoS ONE 7 7 2012 e41529 10.1371/journal.pone.0041529
21. E.C. Darcissac, M.J. Truong, J. Dewulf, Y. Mouton, A. Capron, and G.M. Bahr The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells J Virol 74 17 2000 7794 7802
22. http://www.cytodyn.com/drug-pipeline/cytolin [accessed 15.10.14]
23. http://www.cancer.gov/drugdictionary?cdrid=453546 [accessed 20.11.14]
24. http://www.drugbank.ca/drugs/DB04979 [accessed 20.11.14]
25. http://www.aidsmeds.com/archive/HE2000-1647.shtml [accessed 20.11.14]
26. http://mylocation.net/advr/july%2011%202000%20old%20drug%20new%20fight.htm [accessed 20.11.14]
27. http://www.bloodindex.org/immune-theraphy.php [accessed 20.11.14]
28. S. Mehta, and W. Fawzi Effects of vitamins, including vitamin A, on HIV/AIDS patients Vitam Horm 75 2007 355 383
29. G.O. Coodley, H.D. Nelson, M.O. Loveless, and C. Folk Beta-carotene in HIV infection J AIDS 6 3 1993 272 276
30. M.K. Baum, G. Shor-Posner, P. Bonveni, I. Cassetti, and E. Mantero-Atienza et al. Influence of HIV on vitamin status and requirements Ann N Y Acad Sci 669 1992 165 173
31. B. liang, S. Chung, M. Araghiniknam, L.C. Lane, and R.R. Watson Vitamins and immunomodulation in AIDS Nutrition 12 1 1996 1 7
32. S.B. Vaghefi, and E.A. Castellon-Vogel Nutrition and AIDS: an introductory chapter RR Watson, Nutrition and AIDS 1994 CRC Press 1
33. http://www.nutraingredients.com/Research/The-role-of-nutrition-in-living-with-HIV-AIDS [accessed 17.10.14]
34. http://www.aidsmeds.com/articles/multivitamin-slows-1667-24915.shtml [accessed 07.13.14]
35. S. Dreizen Nutrition and the immune response - a review Int J Vitam Nutr Res 49 2 1979 220 228
36. http://www.who.int/elena/titles/bbc/vitamina-hiv-adults/en/ [accessed 07.10.14]
37. J.H. Irlam, M.M. Visser, N.N. Rollins, and N. Siegfried Micronutrient supplementation in children and adults with HIV infection Cochrane Database Syst Rev 12 2010 CD003650 10.1002/14651858.CD003650
38. R.D. Semba, N.M. Graham, W.T. Caiaffa, J.B. Margolick, L. Clement, and D. Vlahov Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection Arch Intern Med 153 18 1993 2149 2154
39. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development.
40. P. Corbeau, and J. Reynes Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection Blood 117 21 2011 5582 5590
41. Y. Levy Immunotherapy in HIV infection; current and future challenges Retrovirology 7 Suppl. 1 2010 I13 10.1186/1742-4690-7-S1-I13
42. A. Bandera, A. Gori, and D. Trabattoni et al. Positive immunomodulatory effects of tucaresol in HIV-infected patients: results from a phase I/II trial after 40 weeks of follow-up Abstract presented at: 10th conference on retroviruses and opportunistic infections (CROI) 10-14 February, Boston, MA 2003 Abstract 654
43. L. Gazzola, G. Marchetti, and A. Bandera et al. Dynamics of T Cells Homeostasis Induced by Tucaresol Abstract presented at: 11th conference on retroviruses and opportunistic infections (CROI) 8-11 February, San Francisco, CA 2004 Abstract 523
44. A. Gori, D. Trabattoni, A. Bandera, M. Saresella, G. Marchetti, and L. Gazzola et al. Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial Antivir Ther 9 4 2004 603 614
45. H.R. Khorram Khorshid, M. Abdollahi, Y.A. Novitsky, M.H. Shahhosseiny, B. Sadeghi, and H. Madani et al. Studies on potential mutagenic and genotoxic activity of setarud DARU J Pharm Sci 16 4 2008 223 228
46. K. Paydary, S. Emamzadeh-Fard, H.R. Khorram Khorshid, K. Kamali, S. SeyedAlinaghi, and M. Mohraz Safety and efficacy of Setarud (IMOD™) among people living with HIV/AIDS: a review Recent Pat Antiinfect Drug Discov 7 1 2012 66 72
47. M. Mohraz, A. Sedaghat, S. Seyed Alinaghi, H. Asheri, S. Mohammaddoust, and F. Gharibdoost et al. Post marketing surveillance on safety and efficacy of IMOD in Iranian patients with HIV/AIDS Infect Disord Drug Targets 13 1 2013 71 74
48. http://www.cehd.org/resveratrol-research/resveratrol-a-possible-tool-fortreating-hiv/ [accessed 17.10.14]
49. Z. Lin, J. Li, and D. Fang SIRT1 involvement in virus-mediated diseases JSM Microbiol 2 1 2014 1006 http://www.jscimedcentral.com/Microbiology/microbiology-2-1006.php [accessed 20.10.14]
50. A. Heredia, C. Davis, and R. Redfield Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol J Acquir Immun Defic Syndr 25 3 2000 246 255
51. C.L. Clouser, J. Chauhan, M.A. Bess, J.L.V. Oploo, D. Zhou, S. Dimick-Gray, L.M. Mansky, and S.E. Patterson Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine Bioorg Med Chem Lett 22 21 2012 6642 6646
52. E.C. Darcissac, M.J. Truong, J. Dewulf, Y. Mouton, A. Capron, and G.M. Bahr The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells J Virol 74 17 2000 7794 7802
53. http://www.cancer.gov/clinicaltrials/search/view?cdrid=616946&version=HealthProfessional&protocolsearchid=13485787 [accessed 20.10.14]
54. http://www.businesswire.com/news/home/20040303005223/en/Hollis-Eden-Pharmaceuticals-Presents-Data-Molecular-Mechanism-Action#.VG16kTSUcSF [accessed 20.10.14]
55. http://www.aidsmeds.com/archive/HE2000-1647.shtml [accessed 20.10.14]
56. http://www.clinicaltrials.gov/ [accessed 20.10.14]
57. http://www.learnr.pro/content/31084-hiv-and-aids-basic-elements-and-priorities/255 [accessed 20.10.14]
58. http://www.eurekalert.org/pub-releases/1999-02/AVRC-AFAV-250299.php [accessed 20.10.14]
59. http://mylocation.net/advr/july%2011%202000%20old%20drug%20new%20fight.htm [accessed 20.10.14]
60. C. Vandergeeten, R. Fromentin, S. DaFonseca, M.B. Lawani, I. Sereti, M.M. Lederman, M. Ramgopal, J.P. Routy, R.P. Sékaly, and N. Chomont Interleukin-7 promotes HIV persistence during antiretroviral therapy Blood 121 21 2013 4321 4329
61. R. Thiébaut, J. Drylewicz, M. Prague, C. Lacabaratz, S. Beq, and A. Jarne Quantifying and predicting the effect of exogenous interleukin-7 on CD4+T cells in HIV-1 infection PLoS Comput Biol 10 5 2014 e1003630 10.1371/journal.pcbi.1003630
62. Schein PS, Kalebic T. Suppression of HIV expression by organic thiophosphate US 5824664 A, 1998.
63. Hirsch GP, Bayless RK. Treating aids and HIV infection with methionine, US 5292773 A, 1994
64. Oge WD, Herzenberg LA. Treatment of diseases associated with cysteine deficiency, US 5607974 A, 1997.
65. Saxena B, Rathnam P, Bomshteyn A. Anti-HIV-1 activity of betulinol derivatives. US 20060019934 A1, 2006.
66. Goldberg DI, White RD, Wilson DM. Method of reducing or preventing toxicity associated with antiretroviral therapy by stimulation of the intracellular gluthatione level. EP 0572110 A2, 1993.
67. Tsai HH, Hwang SM, Kung PC. Use of plant extracts for treatment of HIV, HCV and HBV infections. US 5837257 A, 1998.
68. Redfield RR, Davis CE, Heredia JA. A hydroxylated stilbene that promotes dna synthesis in a virally-targeted cell such as resveratrol; a nucleoside analogue having antiviral activity such as dideoxyinosine. US 6479466 B1, 2002.
69. Boojamra CG, Lin KY, Mackman RL, Markevitch DY, Petrakovsky OV, Ray AS, Zhang L. Nucleoside phosphonate conjugates as anti HIV agents. EP 1778251 B1, 2011.
70. Chan CKL, Courchesne M, Halab L, Moinet C. Novel c-21-keto lupane derivatives preparation and use thereof. WO 2009082818 A1, 2009.
71. Moinet C, Halab L, Liu B, Denis R, Poisson C, Nguyen-Ba P, Bubenik M, Turcotte N, Chan CKL. Novel 17 beta lupane derivatives. EP 2257567 A1, 2010.
72. Kniskern PJ, Hagopian A, Burke P. Expression of fusion protein of HIV envelope and HBsAG. US 5130247 A, 1992.
73. Chen J, Cloyd MW, Lee K, Paar D, Wang L. Methods and compositions involving thymidine phosphorylase as a marker for HIV infection, aids progression, and drug resistance. EP 1444521 A1, 2004.